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Abstract
Background: Despite the availability of evidence-based treatments for depression, a large proportion of patients
remains untreated or adequate treatment is initiated with delay. This situation is particularly critical in primary care,
where not only most individuals first seek help for their mental health problems, but also depressive disorders –
particularly mild to moderate levels of severity – are highly prevalent given the high comorbidity of chronic
somatic conditions and depression. Improving the access for evidence-based treatment, especially in primary
care, is hence a priority challenge in the mental health care agenda. Telephone usage is widespread and has
the potential of overcoming many barriers that individuals suffering from mental health problems are facing: Its
implementation for treatment delivery presents an option for optimisation of treatment pathways and outcomes.
Methods/design: This paper details the study protocol for a randomised controlled trial (RCT) evaluating the
effectiveness of a telephone-administered short-term cognitive-behavioural therapy (T-CBT) for depression as
compared to treatment as usual (TAU) in the Swiss primary care setting. The study aims at randomising a total of
216 mildly to moderately depressed patients, which are either identified by their General Practitioners (GPs) or
who self-refer to the study programme in consultation with their GP. The trial will examine whether telephone-
delivered, manualised treatment leads to clinically significant reduction in depression at follow-up. It will further
investigate the cost-effectiveness and acceptability of the intervention in the primary care setting.
Discussion: Conducting a low-intensity treatment on the telephone allows for greater flexibility for both patient
and therapist, can grant more anonymity and can thus lead to less hesitation in the patient about whether to
attempt treatment or not. In order to benefit from this approach, large-scale studies need to prove superior
effectiveness and cost-effectiveness of telephone-delivered therapy over routine care for patients with mild to
moderate depression.
Trial registration: ClinicalTrials.gov NCT02667366. Registered on 3 December 2015.
Keywords: Telephone-delivered psychotherapy, Evidence-based treatment, Short-term CBT, Primary care, Access
to mental health services, Mild to moderate depression
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Background
Depressive disorders are a common mental health con-
dition with a high prevalence and burden of disease.
With a 12-month prevalence of approximately 8% it is
one of the most widespread mental disorders [1] and
causes a high degree of personal suffering and impair-
ment. It is also associated with high societal costs, thus
presenting a substantial challenge to the health care
system, not least in view of the considerable direct and
indirect costs implied [2]. In Switzerland, for example,
the total cost caused by depression on a national level
amounts to more than 8 billion Swiss Francs per
year [3]. Estimations predict a further increase in
depression-related disease burden in the next 20 years;
depression will represent the second most important
factor for impairment and premature mortality after
cardiovascular diseases in highly economically devel-
oped countries [4].
Mild to moderate depression presents a particular
challenge to the health care system for various reasons.
Firstly, there is a high prevalence of these levels of
depression among the general population. In a national
representative data sample in the US, an overall preva-
lence of 20% of any depressive symptoms was assessed,
the majority of which were mild to moderate depressive
symptoms [5]. Secondly, the nature of mild to moder-
ate depressive episodes involves the risk of exacerbating
symptoms and developing chronic or more severe
forms of the depressive disorder if they remain un-
treated, are inadequately treated or if treatment is initi-
ated with delay [6]. In order to treat depressive
disorders efficiently and in order to avoid deterioration
of the individuals’ condition and increase of the societal
burden, the provision of timely and adequate treatment
is of great importance. Therefore, inappropriate health
care for patients suffering from depression poses a
third challenge for the health care system: according to
international trials, treatment adequacy is particularly
low in mild to moderate degrees of depression [7]. In
primary care, almost two thirds of patients suffering
from mild depression and one third of patients suffer-
ing from moderate depression receive exclusively anti-
depressant medication [6], even though international
guidelines recommend psychotherapy and low-intensity
treatment – with a particular focus on cognitive-behav-
ioural therapy (CBT) – as first-line treatment [8, 9]. These
clinical guidelines further explicitly advise against the
application of antidepressant medication in mild
degrees of severity except for special situations, due to
the unfavourable risk-benefit ratio with regard to un-
desirable side effects. Treatments that are not compli-
ant to clinical guidelines consequently present a
serious problem for patients suffering from less severe
depressive disorders.
However, initiating adequate psychological treatment
is impeded by various barriers to access care on an in-
dividual level (fear of stigma, lack of time, comorbid
somatic conditions, cultural factors), on the provider
level (inadequate diagnostics and knowledge about
mental disorders in primary care, lack of time) and on
the systemic level (waiting lists, insufficient intercon-
nectedness between health care professionals, insuffi-
cient treatment capacity) [10].This inadequate supply
situation particularly affects primary care, given the
high prevalence rates of depression there (ranging be-
tween 5 and 30%) [11] with general practitioners (GP)
being in charge of detecting patients, motivating them
for treatment and initiating it. The latter comprises
either treatment in primary care or the referral to
specialized care, which is rather seldom (e.g. in
Switzerland only approx. 13%, (e.g. [12])).
Given these challenging tasks in (primary) care, low-
threshold and intensity-appropriate (so-called `low in-
tensity´) formats of psychological treatments, such as
telephone-administered psychotherapy, may contribute
to a better access to evidence-based treatment.
Telephone-administered psychotherapy
One increasingly promising approach to overcoming the
aforementioned barriers is the application of treatments
with the help of remote communication. Telephone
and particularly mobile phone is an omnipresent and
well-accepted means of communication [13], which has
become a reliable tool for managing and delivering care
in many areas of the health care system and for a var-
iety of somatic conditions [14, 15]. Telephone-based
interventions focusing on mental health have further
been proven beneficial and effective in providing CBT
for a variety of mental disorders and symptoms, includ-
ing anxiety disorders in older patients [16], insomnia,
health-related quality of life and disability [17] and a
variety of conditions where mental health problems co-
occurred with chronic somatic disorders. Telephone-
delivered psychotherapy – with a special emphasis on
CBT (T-CBT) – also shows promising results for the
treatment of depression in international meta-analyses
[18]. Trials that have thus far investigated this ap-
proach for depression in primary care settings have
shown lower attrition rates and equivalent improve-
ment in symptom severity at posttreatment compared
to face-to-face treatment [19, 20]. Thus, T-CBT could
lead to expanded, more flexible, and accessible psycho-
therapeutic services with the additional option of low-
ering costs.
However, the majority of trials aim at the reduction
of depressive symptoms in patients suffering from
chronic and distressing somatic conditions, such as
HIV/AIDS, multiple sclerosis and cancer [21–23].
Watzke et al. BMC Psychiatry  (2017) 17:263 Page 2 of 9
Other studies do not examine T-CBT as a stand-alone
treatment for depression; for example, some studies
focus on T-CBT in depression care management [24, 25]
or as adjunct support in order to ensure adherence to
pharmacological treatment. It is also insufficiently clarified
whether T-CBT has long-lasting effects on the patients’
mental health and if long-lasting effects would pertain to a
less severely depressed patient sample [19].
Despite promising results for T-CBT for depression
in primary and specialist care [18, 26], it is necessary
to investigate an intensity-appropriate therapy deliv-
ered via telephone as a stand-alone intervention as
well as to examine effects that go beyond the post-
treatment improvement for patients with mild to
moderate depression. Lastly, large-scale effectiveness
studies with more specific patient samples are required
to add to a solid evidence-base and need to be adopted
to the specific characteristics of various health care
systems. The proposed trial enables us to investigate
whether T-CBT as a stand-alone treatment element
can improve the acute treatment of mild to moderate
depression, which will be undertaken in the Swiss
health care system.
Objectives
Our study aims at evaluating the effectiveness of a
telephone-delivered CBT as an add-on treatment to rou-
tine care in primary care patients with mild to moderate
depression under clinically representative conditions.
Secondary objectives include the evaluation of T-CBT’s
cost-effectiveness compared to treatment as usual (TAU).
Further objectives are the examination of process vari-
ables. Particularly, patients’ and therapists’ acceptance
and satisfaction with the telephone-intervention as well
as process quality of the treatment and therapeutic alli-
ance will be investigated.
Hypotheses
Primary hypothesis is that the addition of T-CBT to rou-
tine care is superior to routine care alone (treatment as
usual, TAU) in reducing depression symptom severity
measured with the Patient Health Questionnaire (PHQ-
9) at 12-month follow-up. Main secondary hypotheses
are that T-CBT is more effective at reducing symptom
severity at end of treatment (t1) and that T-CBT is
cost-effective compared to TAU.
Ethical approval
Approval for the study has been obtained from the
responsible local Ethics Committee of the Canton of
Zurich (Ref. Nr. 2015–0417). The study will be con-
ducted according to the principles of the Declaration of
Helsinki and in line with the Guidelines for Good Clin-
ical Practice (GCP).
Methods: Participants, interventions, and
outcomes
Study design
The proposed study is a prospective randomised con-
trolled effectiveness trial of short-term T-CBT compared
to treatment as usual in primary care patients with mild
to moderate depression. Both study arms will receive
treatment as usual (TAU). A total of 216 individuals
who fulfil inclusion criteria are intended to be rando-
mised in either active treatment or control condition
with a 1:1 allocation. Outcomes will be assessed at base-
line (t0), at the end of treatment (t1, i.e. 4 months after
baseline in CG) and 12 months (t2) after baseline. Table
1 presents a structured summary of the trial by provid-
ing items from the WHO Trial Registration Data set.
Participants
The trial aims at randomising a total of 216 patients with
mild to moderate depression, who are either recruited
by a participating GP in Zurich or who take notice of
the study advertisement in the media (esp. regional
newspapers) and thus self-initiate study participation in
consultation with their GP.
Inclusion criteria
Eligible study participants need to meet the following
inclusion criteria: a) age of at least 18 years, b) PHQ-9
score of >5 and ≤15, c) a diagnosis of mild or moderate
depression according to ICD-10, more specifically a
single episode major depressive disorder or recurrent
depressive disorder with a mild or moderate degree of
severity (i.e., F32.0, F32.1, F33.0, F33.1) and d) given in-
formed consent.
Exclusion criteria
The following criteria lead to exclusion from the study:
a) chronic depression i.e. symptoms of at least 2 years
duration, b) suicidality, suicidal tendency or suicidal idea-
tion, c) insufficient knowledge of the German language, d)
taking part in psychotherapeutic / psychological treatment
currently or in the last 3 months, e) a physical or mental
condition that does not allow the completion of question-
naires. Psychopharmacological treatment is only an exclu-
sion criteria, if medication is not stable for at least 3
months prior to study inclusion.
Study interventions
T-CBT (intervention group)
The intervention group (IG) will receive T-CBT in
addition to TAU, which is a short-term telephone-
delivered psychotherapy. The therapy programme is a
manualised cognitive-behavioural therapy (CBT) con-
sisting of one initial face-to-face appointment and 8–10
subsequent telephone sessions (+ 2 optional booster
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sessions) with the study therapist. Telephone contacts
will take place on a weekly and – after the first four
sessions – on a bi-weekly basis and will last 3–4 months
in total. Each telephone contact should last between 30
and 40 min and will be audio recorded for the sake of
assessing treatment integrity and evaluating treatment
process variables.
The therapy programme is a translated and culturally
adapted version of the programme Creating a balance
developed in the US [24, 27]. The German version (“Ins
Gleichgewicht finden”) has been evaluated as part of a
stepped care trial [28], i.e. was part of a complex inter-
vention of stepped care which was evaluated as a whole.
For the proposed study, the manual has been adapted
slightly according to special characteristics and cultural
features of the Swiss population (especially adaption of
the case studies, e.g. using typical Swiss expressions
and names).
The manualised programme comprises the central
components of CBT for depression: the first part of the
programme focuses on behavioural activation and the
subsequent chapters centre upon strategies of cognitive
restructuring. Further essential treatment elements are
psycho-education and relapse prevention. After a max-
imum of 10 sessions there is the option of adding up to
two booster sessions for enhancing long-term mainten-
ance of treatment effects. Patients receive a workbook
which they work with independently between sessions and
then discuss materials with the telephone therapist. More-
over, since regular symptom monitoring (PHQ-9) is part
of the telephone treatment, patients learn to monitor
themselves concerning their depressive state. Despite the
strong structure and guidance provided by the therapist,
the programme has a strong self-help character and thus
requires patients to delve into the contents and acquire
skills themselves with support of the therapist.
Table 1 WHO Trial Registration Data Set
Data category Information
Primary registry and trial identifying number ClinicalTrials.gov NCT02667366
Date of registration in primary register 3 December 2015
Sources of monetary or material support Gottfried and Julia Bangerter-Rhyner-Foundation (Bangerter-Stiftung) and Swiss Academy of Medical
Sciences (Schweizerische Akademie der Medizinischen Wissenschaften, SAMW)
Primary sponsor(s) Prof. Birgit Watzke, University of Zurich
Contact for public queries M.Sc. Elisa Haller
Department of Clinical Psychology and Psychotherapy Research
Binzmühlestrasse 14/16, CH-8050 Zürich
Switzerland
e.haller@psychologie.uzh.ch
Contact for scientific queries Prof. Dr. Birgit Watzke
Department of Clinical Psychology and Psychotherapy Research Binzmühlestrasse 14/16, CH-8050 Zürich
Switzerland
b.watzke@psychologie.uzh.ch
Public title Telephone-Intervention/Information for Depression (TIDe)
Scientific title Effectiveness and cost-effectiveness of a telephone-based cognitive-behavioural therapy in primary
care for mild to moderate depression
Countries of recruitment Switzerland
Health condition(s) or problem(s) studied Mild to moderate depression
Intervention(s) Telephone-delivered short-term cognitive-behavioural therapy
Key inclusion and exclusion criteria Inclusion criteria: Age ≥ 18 years, mild to moderate depression according to ICD-10, PHQ-9 > 5
and ≤15, able to fill in questionnaires, German language
Exclusion criteria: suicidality or suicidal tendency, currently or in last 3 months in psychotherapeutic
treatment, chronic depression or dysthymia, severe depression, psychopharmacological medication
that is not stable for 3 months prior to enrolment.
Study type Randomised-controlled superiority trial
Date of first enrolment January 2016
Target sample size 216
Recruitment status Recruiting
Primary outcome(s) Symptom severity at t2 (PHQ-9)
Key secondary outcomes Symptom severity at t1 (PHQ-9),
Response defined as 50% reduction from t0 to t1,remission defined as <5 points in the PHQ-9 at t2
and t1, relapse defined as ≥5 points in the PHQ at t2 following remission at t1, cost-effectiveness
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T-CBT will be conducted by three study therapists in
training, who are clinical psychologists and are in CBT
training with a minimum of 2 years of experience in the
treatment of patients predominantly suffering from
affective disorders. The study therapists receive training
in T-CBT and supervision will be provided every month
by a senior study team member (BW).
Adverse events will be regularly and systematically
monitored by the telephone therapist. Emergency plans
will be prearranged in case of acute suicidality, e.g. calling
the emergency services. In case of an emotional decom-
pensation there will be the possibility to meet in a face-to-
face session or to choose a more intensive treatment (e.g.
inpatient treatment).
Text messages (control group)
Patients in the control group (CG) will receive TAU and
a minimal intervention additionally: This minimal inter-
vention entails a total of 10 text messages which contain
factual information on depression. The text messages
will be sent to the patient on a weekly and later bi-
weekly basis, i.e. in the same frequency as telephone-
sessions in the IG. The receiver cannot and is not
required to reply to the messages. The messages con-
tain short neutral information on different aspects of
depressive disorders, for example on prevalence, clin-
ical picture, course and the social implications of the
depressive disorder (e.g. “Depression is very common.
More than every fifth person experiences depression
once in their life”). The text messages should be of
interest for the patients in the control condition with-
out having a therapeutic effect. The contents of the text
messages differ from a psychoeducational intervention
in the sense that they a) do not follow a systematic and
structural knowledge transfer and b) do not convey
strategies that enable a health-promoting lifestyle. The
minimal intervention is amended to TAU to control for
effects resulting from purely contacting patients and
reminding them. It can be assumed that they might
have a minimal effect on patients on the short term,
but not a lasting (therapeutic) one.
Outcomes and measures
Outcome assessment
Outcomes will be assessed via self-report paper-pencil
questionnaires at baseline, post-intervention and follow-
up, which will be sent to the patient via mail. The pri-
mary outcome of effectiveness refers to a change in
symptom severity from t0 (baseline) to t2 (12 months
after baseline), measured by the German version of
the PHQ-9.
Secondary outcome parameters will include the change
in depressive symptoms from t0 to t1, response defined
as a 50% reduction in the PHQ-9 value from t0 to t1,
remission defined as <5 points in the PHQ-9 at t2 and
t1, and relapse defined as ≥5 points in the PHQ-9 at t2
following remission at t1. Further secondary outcome is
change in health-related quality of life (HrQoL)
assessed by the SF-12. Furthermore, the incremental
cost-effectiveness of T-CBT compared to TAU will be
analysed based on (direct and indirect) costs and
quality-adjusted life years (QALYs) observed within the
12-month follow-up period.
In addition to outcome measures, there will be an as-
sessment of structural and process variables. For the IG,
these will entail amount and duration of telephone con-
tacts as well as contents of the sessions. Additional assess-
ments take place at the beginning of each telephone
session in order to monitor symptom severity and meas-
ure therapist ratings regarding the therapeutic alliance
between patient and therapist. Therapists’ and patients’
acceptance of and satisfaction with T-CBT will be assessed
with a self-constructed questionnaire based on instru-
ments from the study team’s prior research.
Outcome measurements
Patient Health Questionnaire (PHQ-D): is the German
version of a patient rating instrument covering the se-
verity and frequency of symptoms of depression (9
items), generalised anxiety syndrome (7 items), somato-
form syndrome (13 items) and panic syndrome (11
items). The instrument demonstrates high levels of
validity in the diagnosis and evaluation of symptom
severity of major depressive disorder in primary care
patients [29]. The PHQ-D is a well-accepted, reliable
instrument and shows diagnostic validity [30]. The de-
pression subscale (PHQ-9) covers severity/frequency of
the primary and secondary symptoms of major depres-
sive disorder [29] and has proven reliability and validity
for the use in primary care [31].
Short Form − 12 (SF-12): is the short version of the
Short Form 36 Health Survey and assesses overall
health-related quality of life. The 12 items constitute
the two subscales physical and mental health. It is an
internationally well-established instrument with proven
psychometric properties [32].
General Self-Esteem Scale (GSES): is a revised version
of the Rosenberg Self-Esteem-Scale and captures global,
unidimensional self-esteem. Ten statements regarding
beliefs about personal ability, value and attitudes toward
oneself are rated on a 4-point Likert scale. Reliability
and validity show satisfactory values [33].
General self-efficacy scale (GSE): is a one-dimensional
self-rating scale measuring the global optimistic beliefs
about one’s self [34]. On a four-point Likert scale, sub-
jects indicate their level of agreement with ten state-
ments about the self-related expectation of coping with
a difficult situation.
Watzke et al. BMC Psychiatry  (2017) 17:263 Page 5 of 9
Depression-related self-management behaviour: this
five-item scale was created to examine the respondents’
perceived ability to cope with depressive symptoms and
complaints [35] and to assess to which extent patients
integrate pleasant activities in their daily lives.
Client Sociodemographic and Service Receipt In-
ventory (CSSRI): will be employed to measure health
care utilisation and productivity loss [36]. A slightly
adapted version of the instrument for the Swiss health
care system will assess the type and frequency of all
health services the respondent used as well as absence
from work during the last 6 months.
EQ-5D-5 L: Health-related quality of life for the eco-
nomic analysis will be measured using the EQ-5D-5L,
an internationally established instrument to derive util-
ities (EQ-5D index) for cost-effectiveness analyses [37]
(www.euroqol.org).
Psychotherapy Motivation Questionnaire (FPTM-23):
is the short version of the Questionnaire on Psychotherapy
Motivation [38], a measure used to assess the motivation
for undertaking a psychotherapy. Three out of six sub-
scales – psychological stress, hope and denial of need for
help – are used in this study. These sub-scales also indi-
cate sufficient and good internal consistency [38].
Participant timeline
The SPIRIT flow diagram of enrolment, pre-study screen-
ing, interventions and assessment is provided in Fig. 1.
Sample size
With a total sample size of 172 evaluable patients (IG:
n = 86; CG: n = 86), a medium effect size (d = .44) can be
detected in the primary outcome measure between T-CBT
and TAU in the planned ANCOVA with a two-sided
hypothesis, significance level of 0.05 and statistical power of
90% (when error variance is reduced to 20% by the covariate
(baseline depressive symptoms)). With 20% loss-to-follow-
up, 216 patients need to be randomised for both ITT and
complete-case analysis to reach a power of 90%. Since prior
projects suggest that approx. 60% of the patients at risk will
meet the inclusion criteria and that again roughly 60% of
depressive patients in primary care will participate in the
study, 600 patients will be screened for inclusion.
Recruitment and study procedure
The recruitment process entails two main strategies. In the
first instance, study patients will be recruited by 15 partici-
pating GPs in the area of Zurich, Switzerland. All patients
visiting their GP who are at risk for depression, especially
those who present diffuse somatic or chronic somatic
symptoms [8] will be screened for depressive symptoms.
The GP who has been trained by the study team has two
alternative ways of proceeding with study inclusion: a) the
GP carries out diagnostics and conducts study enrolment
by checking eligibility criteria, obtaining the consent form
and handing out the baseline questionnaire; b) the GP al-
ternatively refers the patient directly to the study team: If
the patient consents to being contacted, a member of the
study team will call the patient and will carry out ICD-10
diagnosis and study enrolment over the telephone. Baseline
questionnaire and consent form will be sent via mail.
The second strategy of participant recruitment will be
patient-initiated enrolment. Newspaper articles describ-
ing the study and the option of participating will be pub-
lished in regional newspapers and on the homepage of
clinical units in Zurich. Patients initiating contact with
the study team via telephone will be screened by the
study team, who will carry out ICD-10 diagnosis and
study enrolment over the telephone. Additionally, pa-
tients need to consult their GP and inform them about
study participation. Signed consent forms and baseline
questionnaire will be sent via mail (see section “consent
and confidentiality”). After the study team receives the
signed informed consent and baseline questionnaire, pa-
tients are enrolled and subsequently randomised.
Fig. 1 SPIRIT flowchart of study participants
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Patients allocated to the IC will be called by a member
of the study team to arrange an appointment between
patient and study therapist ideally within 1 week after
randomisation. If a patient is assigned to the CG, the
first text message will be sent within a week after ran-
domisation. Four months and 12 months after t0, all pa-
tients will receive mail from the study team containing
the t1-questionnaire and a stamped envelope to return
the completed questionnaire. If a patient fails to return
the questionnaire, at first one written reminder for filling
out the questionnaire will be sent, and, if still unsuccess-
ful, the patient will be reminded by a phone call. For
each completed follow-up questionnaire, patients will
receive a CHF 25.-shopping voucher.
Methods: Assignment of interventions
Allocation
Randomisation and sequence generation
All eligible and consenting patients will be allocated ran-
domly to either IG or CG after completion of baseline
measurements. The computer-generated randomisation
list with block sizes of 10, which contains the enrolment
number and an assigned code for allocation to study
condition, was prepared by one of the study team mem-
bers. A research assistant of the unit not involved in the
recruitment procedure prepared sequentially numbered
opaque envelopes for each enrolment number separately
and placed each enrolment number with the corre-
sponding allocation code of the randomisation list in the
according envelope. Study allocation will be concealed
by a member of the study team (EH) by opening the en-
velope that corresponds with the enrolment number and
by subsequently contacting the patient via telephone in
order to declare the allocation result.
Methods: Data management and analysis
Data management
Data coding and entry of the paper-based data will be
performed manually by a research assistant trained in
standardised coding and being supervised by the study
coordinator (EH), who will also check accuracy of data
entry by conducting sampling inspections. Data will be
stored securely and in a pseudonymised manner. Elec-
tronic data will be saved on a secure server with access
restriction at the University of Zurich including daily
backup and accessible exclusively by the study coordin-
ator and principal investigator. After study completion
electronic data will be saved on a separate password pro-
tected medium (external hard drive), which will be
stored together with print data in a lockable cabinet of
the Department of Clinical Psychology and Psychother-
apy Research. During study trial as well as after comple-
tion of the study Principal Investigator and Study
Coordinator exclusively have access to the data. In
accordance with the national regulations in Switzerland
data will be stored for 10 years after termination of the
trial. Since all data will be collected in one study site a
data monitoring committee was not established.
Statistical analysis
Data will be analysed according to the CONSORT state-
ment [39]. The primary analysis will refer to the
intention-to-treat (ITT) sample that includes all rando-
mised eligible patients. Multiple imputation of missing
data will be performed if data required for the primary
analysis are missing. For the primary outcome ‘PHQ-9
change in depressive symptoms from t0 to t2’ an analysis
of covariance (ANCOVA) with baseline PHQ-9 as covar-
iate and group as fixed effect will be calculated in order
to estimate and test the difference between the IG and
the CG. The secondary outcomes will be examined in an
exploratory manner with appropriate procedures. Sensi-
tivity analyses will be performed by application of an al-
ternative imputation method (last observation carried
forward, LOCF), inclusion of further covariates and re-
striction to complete cases or to the per protocol popu-
lation (PP sample) consisting of patients without major
violations of the study protocol. The decision whether a
protocol violation is judged as major will be blindly met
by the study team. Interim analyses are not planned.
The significance level will be set at 5% (two-sided). Stat-
istical analyses will be carried out with SPSS, Version 23
(IBM Corp., Armonk, NY, USA).
In order to determine the cost-effectiveness of T-CBT,
health care utilisation and productivity loss measured
with an adapted version of the CSSRI will be monetarily
valued by Swiss unit costs to calculate direct and indir-
ect costs. Quality-adjusted life years (QALYs) will be
calculated based on the EQ-5D index [40], and the
incremental cost-effectiveness ratio (ICER) will be com-
puted. To adjust for baseline differences and to evaluate
the uncertainty of the estimates, net-benefit regressions
will be conducted and cost-effectiveness acceptability
curves will be derived therefrom.
Consent and confidentiality
Informed consent will be obtained from all eligible
patients before study enrolment: Interested and eligible
patients are informed by their GPs or by the study team
about the purpose of the study. They are handed out a
detailed patient information document and a consent
form to take home and read through it carefully. After
patients return the signed informed consent, patients
will be enrolled into the study. After study enrolment,
patients will fill out baseline questionnaire and will sub-
sequently be randomised. The study information docu-
ment and informed consent form was approved by the
Ethics Committee of the Canton of Zurich.
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The principal investigator (BW) affirms and upholds the
principle of the participant’s right to privacy and that they
shall comply with applicable privacy laws. Especially, ano-
nymity of the participants shall be guaranteed when pre-
senting the data at scientific meetings or publishing them
in scientific journals. Individual subject medical informa-
tion obtained as a result of this study is considered confi-
dential and disclosure to third parties is prohibited. Subject
confidentiality will be further ensured by utilising subject
identification code numbers to correspond to treatment
data in the computer files, which means that all data will
be collected and stored in a pseudonymised manner. The
key to the subject identification code numbers is securely
and separately stored from the pseudonymised data.
Discussion
The presented trial aims at investigating the effectiveness
and cost-effectiveness of a telephone-delivered short-term
CBT compared to routine care for patients suffering from
mild to moderate depressive disorders in primary care. A
large impact of the results on clinical practice is to be ex-
pected: Given the relevance of depressive disorders and the
mis- and undersupply for these disorders in terms of
evidence-based treatments, the approach of T-CBT could
lead to expanded and more flexible low-threshold psycho-
therapeutic services. If the study shows that T–CBT is
more effective (and cost-effective) than TAU, it could be
used to improve the treatment for (primary care) patients
suffering of depression. Firstly, a larger proportion of pa-
tients in need could be reached with this approach, so the
access to psychological care would be enhanced. Secondly,
affected patients would receive evidence-based psycho-
logical treatments, which are appropriate for their specific
conditions. Both factors could result in an improved treat-
ment pathway and outcome. As these effects would be very
beneficial for both the individual patient (with less suffer-
ing, fewer symptoms and better functional health) as well
as for society and the health system (lower direct and in-
direct costs), an implementation in routine mental health
care seems to be indicated in case of positive study results.
As the trial will be embedded in routine care, it will also
provide information for implementation and roll out.
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